Recent News
23 Jun 2017
GenSight Biologics successfully raises €22.5 million from leading investors in the US and Europe
22 Jun 2017
Proteon Therapeutics Announces $22.0 Million Private Placement
20 Jun 2017
eFFECTOR Therapeutics to Collaborate with Pfizer and Merck KGaA, Darmstadt, Germany to Evaluate a Novel Immuno-oncology Combination in Microsatellite Stable Colorectal Cancer
12 Jun 2017
Sientra to Acquire Miramar Labs®
5 Jun 2017
Research Suggests Possible New Treatment for EGFR-Positive Lung Cancer
9 May 2017
Takeda and GammaDelta Therapeutics Announce Collaboration to Advance Tissue-derived gamma delta (γδ) T Cells
4 May 2017
CRISPR Therapeutics Appoints Samarth Kulkarni, Ph.D. as President, Expanding Role Beyond Chief Business Officer To Oversee U.S. Operations
3 May 2017
GammaDelta Therapeutics expands management team led by Paolo Paoletti as CEO
27 Apr 2017
Avedro Announces $42 Million in Funding to Support Commercial Expansion and Pipeline Development
27 Apr 2017
Verona Pharma Announces Pricing of Global Offering
24 Apr 2017
Wilson Therapeutics presented positive final Phase 2 data for WTX101 at EASL Annual Meeting
20 Apr 2017
Lombard Medical Appoints New CEO
4 Apr 2017
Paratek Announces Positive Phase 3 Study of Omadacycline in Community-Acquired Bacterial
31 Mar 2017
Dynex Technologies Acquired By Telegraph Hill Partners
30 Mar 2017
Avillion signs Clinical Co-Development Agreement with Merck to Advance Anti IL-17 A/F Nanobody® in Psoriasis
27 Mar 2017
Allergan and Paratek Announce Positive Results From Two Phase 3 Trials of Sarecycline for the Treatment of Moderate to Severe Acne
22 Mar 2017
Verona Pharma Enters Global Strategic Clinical Development Services Agreement with QuintilesIMS for RPL554
21 Mar 2017
SutroVax Announces Closing of $64M via Series B Financing
16 Mar 2017
Proteon Therapeutics Announces Full-Year 2016 Financial Results and Changes to the Ongoing Phase 3 PATENCY-2 Clinical Trial
22 Feb 2017
Verona Pharma Commences further RPL554 Phase 2a Clinical Trial
21 Feb 2017
GenSight Biologics Completes Enrollment of REVERSE Phase III Study of GS010 in the treatment of Leber’s Hereditary Optic Neuropathy
18 Jan 2017
Paratek Announces Completion of Enrollment in Omadacycline Phase 3 Community-Acquired Bacterial Pneumonia Study
20 Dec 2016
GenSight Biologics reports sustained visual acuity gain at 78 weeks in its Phase I/II Study with GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON)
19 Dec 2016
Lombard Medical and MicroPort Scientific Corporation Announce Strategic Partnership and Investment Agreement
13 Dec 2016
Proteon Therapeutics Announces Top-Line Data from Phase 3 PATENCY-1 Clinical Trial of Investigational Vonapanitase in Patients with CKD
5 Dec 2016
Pfizer and Avillion Announce Positive Top-Line Results for Phase 3 BFORE Study of BOSULIF for First-Line Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia
5 Dec 2016
Wilson Therapeutics announces that WTX101 meets the primary endpoint in Phase 2 study in Wilson Disease
7 Nov 2016
MEDIAN Technologies announces a reserved share capital increase to FURUI of €19.6 Million at a €13 per share price
1 Nov 2016
Casebia Therapeutics Press Release: Casebia Therapeutics Announces Appointment of James W. Burns, Ph.D. as President and Chief Executive Officer
26 Oct 2016
IFM Therapeutics Establishes German Subsidiary and Research Site
20 Oct 2016
Proteon Therapeutics Appoints Paul Hastings Chairman of Its Board of Directors
19 Oct 2016
CRISPR Therapeutics Announces Pricing of Initial Public Offering
16 Sep 2016
GammaDelta Therapeutics Raises Seed Funding from Abingworth
8 Sep 2016
Avedro Appoints Dr. Reza Zadno As Chief Executive Officer
25 Jul 2016
Pixium Vision announces CE market approval of IRIS®II, its first bionic vision system
24 Jun 2016
CRISPR Therapeutics Raises Additional $38M as Part of Series B Financing
22 Jun 2016
IFM Therapeutics Raises $27 Million Series A Financing Led by Atlas Venture and Abingworth
17 Jun 2016
Verona Pharma - Proposed Placing to raise c. £44.7 million and Notice of General Meeting
16 Jun 2016
Paratek Announces that Omadacycline Met All Primary and Secondary Efficacy Outcomes Designated by FDA and EMA in a Phase 3 Study in Acute Bacterial Skin Infections; Omadacycline was Generally Safe and Well-Tolerated
14 Jun 2016
Chiasma Announces Corporate Restructuring Plan and Provides Regulatory Update Regarding Mycapssa™
8 Jun 2016
GenSight Biologics announces additional promising results of its Phase I/II study with GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON)
12 May 2016
Final price in Wilson Therapeutics’ initial public offering set at SEK 49 per share – trading on Nasdaq Stockholm commences today
29 Apr 2016
Stryker acquires Stanmore Implants Worldwide Limited
29 Apr 2016
Wilson Therapeutics announces initial public offering on Nasdaq Stockholm
18 Apr 2016
Chiasma Provides Update Regarding FDA’s Complete Response Letter for Mycapssa™ New Drug Application
18 Apr 2016
Avedro Receives FDA Approval for Photrexa® Viscous, Photrexa® and the KXL® System for Corneal Cross-Linking
13 Apr 2016
Epigenomics receives FDA approval for Epi proColon®
24 Mar 2016
Meridian Bioscience Acquires Magellan Diagnostics, Inc.
22 Mar 2016
Senseonics to Ring Opening Bell at the New York Stock Exchange
17 Mar 2016
CRISPR Therapeutics Adds Pablo J. Cagnoni, M.D., to Board of Directors and Names Tony Coles, M.D., Chairman of the Board to Enhance Drug Development and Commercialization Expertise
8 Mar 2016
Tizona Therapeutics Inc Completes $43 Million Series B Financing
29 Feb 2016
Patient in Pivotal Phase III Program of GS010 in Leber’s Hereditary Optic Neuropathy
19 Feb 2016
eFFECTOR Therapeutics Increases its Series B Financing Round to $56M
8 Feb 2016
Sientra Announces Return of All Products to U.S. Market
21 Jan 2016
Abingworth raises $105m for First Dedicated Clinical Co-Development Fund

 

Home

About Us

  1. About Us
  2. Our Team
  3. Transatlantic Reach
  4. Funds

Strategy

  1. Our Strategy
  2. Venture Capital
  3. Clinical Co‑development
  4. VIPEs
  5. Public Markets

Portfolio

  1. Portfolio Companies
  2. Case Studies

Media Centre

  1. Recent News
  2. Archived News
  3. Film

Contact

  1. Contact Us
  2. Send Us Your Proposal
Recent News
23 Jun 2017
GenSight Biologics successfully raises €22.5 million from leading investors in the US and Europe
22 Jun 2017
Proteon Therapeutics Announces $22.0 Million Private Placement
20 Jun 2017
eFFECTOR Therapeutics to Collaborate with Pfizer and Merck KGaA, Darmstadt, Germany to Evaluate a Novel Immuno-oncology Combination in Microsatellite Stable Colorectal Cancer
12 Jun 2017
Sientra to Acquire Miramar Labs®
5 Jun 2017
Research Suggests Possible New Treatment for EGFR-Positive Lung Cancer
9 May 2017
Takeda and GammaDelta Therapeutics Announce Collaboration to Advance Tissue-derived gamma delta (γδ) T Cells
4 May 2017
CRISPR Therapeutics Appoints Samarth Kulkarni, Ph.D. as President, Expanding Role Beyond Chief Business Officer To Oversee U.S. Operations
3 May 2017
GammaDelta Therapeutics expands management team led by Paolo Paoletti as CEO
27 Apr 2017
Avedro Announces $42 Million in Funding to Support Commercial Expansion and Pipeline Development
27 Apr 2017
Verona Pharma Announces Pricing of Global Offering
24 Apr 2017
Wilson Therapeutics presented positive final Phase 2 data for WTX101 at EASL Annual Meeting
20 Apr 2017
Lombard Medical Appoints New CEO
4 Apr 2017
Paratek Announces Positive Phase 3 Study of Omadacycline in Community-Acquired Bacterial
31 Mar 2017
Dynex Technologies Acquired By Telegraph Hill Partners
30 Mar 2017
Avillion signs Clinical Co-Development Agreement with Merck to Advance Anti IL-17 A/F Nanobody® in Psoriasis
27 Mar 2017
Allergan and Paratek Announce Positive Results From Two Phase 3 Trials of Sarecycline for the Treatment of Moderate to Severe Acne
22 Mar 2017
Verona Pharma Enters Global Strategic Clinical Development Services Agreement with QuintilesIMS for RPL554
21 Mar 2017
SutroVax Announces Closing of $64M via Series B Financing
16 Mar 2017
Proteon Therapeutics Announces Full-Year 2016 Financial Results and Changes to the Ongoing Phase 3 PATENCY-2 Clinical Trial
22 Feb 2017
Verona Pharma Commences further RPL554 Phase 2a Clinical Trial
21 Feb 2017
GenSight Biologics Completes Enrollment of REVERSE Phase III Study of GS010 in the treatment of Leber’s Hereditary Optic Neuropathy
18 Jan 2017
Paratek Announces Completion of Enrollment in Omadacycline Phase 3 Community-Acquired Bacterial Pneumonia Study
20 Dec 2016
GenSight Biologics reports sustained visual acuity gain at 78 weeks in its Phase I/II Study with GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON)
19 Dec 2016
Lombard Medical and MicroPort Scientific Corporation Announce Strategic Partnership and Investment Agreement
13 Dec 2016
Proteon Therapeutics Announces Top-Line Data from Phase 3 PATENCY-1 Clinical Trial of Investigational Vonapanitase in Patients with CKD
5 Dec 2016
Pfizer and Avillion Announce Positive Top-Line Results for Phase 3 BFORE Study of BOSULIF for First-Line Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia
5 Dec 2016
Wilson Therapeutics announces that WTX101 meets the primary endpoint in Phase 2 study in Wilson Disease
7 Nov 2016
MEDIAN Technologies announces a reserved share capital increase to FURUI of €19.6 Million at a €13 per share price
1 Nov 2016
Casebia Therapeutics Press Release: Casebia Therapeutics Announces Appointment of James W. Burns, Ph.D. as President and Chief Executive Officer
26 Oct 2016
IFM Therapeutics Establishes German Subsidiary and Research Site
20 Oct 2016
Proteon Therapeutics Appoints Paul Hastings Chairman of Its Board of Directors
19 Oct 2016
CRISPR Therapeutics Announces Pricing of Initial Public Offering
16 Sep 2016
GammaDelta Therapeutics Raises Seed Funding from Abingworth
8 Sep 2016
Avedro Appoints Dr. Reza Zadno As Chief Executive Officer
25 Jul 2016
Pixium Vision announces CE market approval of IRIS®II, its first bionic vision system
24 Jun 2016
CRISPR Therapeutics Raises Additional $38M as Part of Series B Financing
22 Jun 2016
IFM Therapeutics Raises $27 Million Series A Financing Led by Atlas Venture and Abingworth
17 Jun 2016
Verona Pharma - Proposed Placing to raise c. £44.7 million and Notice of General Meeting
16 Jun 2016
Paratek Announces that Omadacycline Met All Primary and Secondary Efficacy Outcomes Designated by FDA and EMA in a Phase 3 Study in Acute Bacterial Skin Infections; Omadacycline was Generally Safe and Well-Tolerated
14 Jun 2016
Chiasma Announces Corporate Restructuring Plan and Provides Regulatory Update Regarding Mycapssa™
8 Jun 2016
GenSight Biologics announces additional promising results of its Phase I/II study with GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON)
12 May 2016
Final price in Wilson Therapeutics’ initial public offering set at SEK 49 per share – trading on Nasdaq Stockholm commences today
29 Apr 2016
Stryker acquires Stanmore Implants Worldwide Limited
29 Apr 2016
Wilson Therapeutics announces initial public offering on Nasdaq Stockholm
18 Apr 2016
Chiasma Provides Update Regarding FDA’s Complete Response Letter for Mycapssa™ New Drug Application
18 Apr 2016
Avedro Receives FDA Approval for Photrexa® Viscous, Photrexa® and the KXL® System for Corneal Cross-Linking
13 Apr 2016
Epigenomics receives FDA approval for Epi proColon®
24 Mar 2016
Meridian Bioscience Acquires Magellan Diagnostics, Inc.
22 Mar 2016
Senseonics to Ring Opening Bell at the New York Stock Exchange
17 Mar 2016
CRISPR Therapeutics Adds Pablo J. Cagnoni, M.D., to Board of Directors and Names Tony Coles, M.D., Chairman of the Board to Enhance Drug Development and Commercialization Expertise
8 Mar 2016
Tizona Therapeutics Inc Completes $43 Million Series B Financing
29 Feb 2016
Patient in Pivotal Phase III Program of GS010 in Leber’s Hereditary Optic Neuropathy
19 Feb 2016
eFFECTOR Therapeutics Increases its Series B Financing Round to $56M
8 Feb 2016
Sientra Announces Return of All Products to U.S. Market
21 Jan 2016
Abingworth raises $105m for First Dedicated Clinical Co-Development Fund
 
Copyright Abingworth 2017